Tyrosine Kinase Inhibitors: A Potential Approach to the Treatment of Hepatocellular Carcinoma

By  

Current Pharmaceutical Design, Vol. 13, Iss. 32, 2007-11 ,pp. : 3301-3304

Bentham Science Publishers

Access to resources Recommend Favorite

Advances in the development of novel aggrecanase inhibitors

By Gilbert Adam M   Bikker Jack A   O'Neil Steven V  

Expert Opinion on Therapeutic Patents, Vol. 21, Iss. 1, 2011-01 ,pp. : 1-12

Informa Healthcare

Access to resources Recommend Favorite

Beyond sorafenib: novel targeted therapies for advanced hepatocellular carcinoma

By Zhu Andrew X  

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 5, 2010-05 ,pp. : 663-672

Informa Healthcare

Access to resources Recommend Favorite

Can Therapy of Hepatitis C Affect the Development of Hepatocellular Carcinoma?

By Kulik Laura M.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 8, 2006-09 ,pp. : 751-757

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Sorafenib (BAY 43-9006) in Hepatocellular Carcinoma Patients: From Discovery to Clinical Development

By  

Current Medicinal Chemistry, Vol. 19, Iss. 7, 2012-03 ,pp. : 938-944

Bentham Science Publishers

Access to resources Recommend Favorite